Aurobindo Pharma up by 4 per cent on USFDA approval
DSIJ Intelligence / 02 Nov 2017
The share price of Aurobindo Pharma surged by 4.5 per cent in intraday trade on Thursday as the company received the USFDA approvals for two drugs.
The share price of Aurobindo Pharma surged by 4.5 per cent in intraday trade on Thursday as the company announced that it has received the USFDA approval for Fexofenadine and Pseudoephedrine HCL Tablets.
Fexofenadine tablets are used for the treatment of allergy symptoms such as Hay Fever while Psuedoephedrine tablets are used as nasal or sinus decongestant.
The stock hit an intraday high of Rs. 796.70 per share, higher by 4.5 per cent and an intraday low of Rs. 763 per share on BSE on Thursday. The stock witnessed a spurt in volume by more than 2.26 times on BSE.
The stock hit its 52-week high of Rs. 805 per share on November 2, 2016 and its 52-week low of Rs. 504 per share on May 29, 2017 on BSE, respectively. At 1058 hours IST, the stock was trading at Rs. 792.50 per share, higher by 4.02 per cent on BSE on Thursday.
Meanwhile, S&P BSE Sensex was trading at 33,635.49 level, higher by 0.10 per cent and NSE Nifty50 was trading at 10,447.60 level, higher by 0.07 per cent on Thursday.